natgillin/translations-raw huggingface dataset:
A compound of formula I according to one of claims 1 to 3, wherein R2 represents OH; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da R2 predstavlja OH; ili sol takvog spoja.
A compound of formula I according to one of claims 1 to 3, wherein n is 1; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da n je 1; ili sol takvog spoja.
A compound of formula I according to one of claims 1 to 3, wherein A is CR6, R6 representing H or alkoxy; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da A je CR6, R6 predstavlja H ili alkoksi; ili sol takvog spoja.
A compound of formula I according to one of claims 1 to 3, wherein R3 is fluorine; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da R3 je fluor; ili sol takvog spoja.
A compound of formula I according to one of claims 1 to 3, wherein R4 is cycloalkyl; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da R4 je cikloalkil; ili sol takvog spoja.
separating the resulting crystallized salt of (aS,βR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol and said resolution agent from the reaction mixture obtained under a); 
razdvajanje dobivene kristalizirane soli (aS,βR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola i navedenog sredstva za razlučivanje iz reakcijske smjese dobivene u koraku a);
optionally recrystallizing or slurry the salt obtained under b) in a suitable solvent; 
proizvoljno rekristaliziranje ili zgušnjavanje soli dobivene u koraku b) u pogodnom otapalu;
A process according to claim 1 wherein the resolution agent is (11bR)-4-hydroxydinaphtho [2,1-d:1',2'-f] [1,3,2] dioxaphosphepin 4-oxide. 
Postupak prema zahtjevu 1 naznačen time da sredstvo za razlučivanje je (11bR)-4-hidroksidinafto [2,1-d:1',2'-f] [1,3,2] dioksafosfepin 4-oksid.
A process according to claim 1, 2 or 3 wherein the suitable solvent under a) is a ketone, an ester, a mixture of a ketone with an aprotonic polar solvent, or a mixture of an ester with an aprotonic polar solvent. 
Postupak prema zahtjevu 1, 2 ili 3 naznačen time da pogodno otapalo pod a) je keton, ester, smjesa ketona sa polarnim aprotonskim otapalom, ili smjesa estera sa polarnim aprotonskim otapalom.
A process according to claim 1, 2 or 3 wherein the suitable solvent under a) is a ketone or a mixture of a ketone with an aprotonic polar solvent. 
Postupak prema zahtjevu 1, 2 ili 3 naznačen time da pogodno otapalo pod a) je keton ili smjesa ketona sa polarnim aprotonskim otapalom.
A process according to claim 5 wherein the ketone is acetone or methyl ethylketone and wherein the aprotonic polar solvent is dimethylsulfoxide or N / N- dimethylformamide. 
Postupak prema zahtjevu 5 naznačen time da keton je aceton ili metil etilketon i pri čemu polarno aprotonsko otapalo je dimetilsulfoksid ili N/N-dimetilformamid.
A process according to claim 5 wherein the suitable solvent is acetone. 
Postupak prema zahtjevu 5 naznačen time da pogodno otapalo je aceton.
A process according to claim 5 wherein the suitable solvent is a mixture of acetone and dimethylsulfoxide. 
Postupak prema zahtjevu 5 naznačen time da pogodno otapalo je smjesa acetona i dimetilsulfoksida.
A process according to any one of claims 1 to 8 wherein the reaction mixture under a) is seeded with seeds of the salt of (aS,βR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol and the resolution agent as defined in any one of claims 1, 2 or 3 before adding the resolution agent to the reaction mixture. 
Postupak prema bilo kojem od zahtjeva 1 do 8 naznačen time da reakcijska smjesa iz a) je zametnuta sa zametcima soli (aS,βR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola i sa sredstvom za razlučivanje kako je definirano u bilo kojem od zahtjeva 1, 2 ili 3 prije dodavanja sredstva za razlučivanje u reakcijsku smjesu.
A process according to any one of claims 1 to 8 wherein the reaction mixture under a) is seeded with seeds of the salt of (aS,βR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol and the resolution agent as defined in any one of claims 1, 2 or 3 after adding the resolution agent to the reaction mixture. 
Postupak prema bilo kojem od zahtjeva 1 do 8 naznačen time da reakcijska smjesa iz a) je zametnuta sa zametcima soli (aS,βR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola i sa sredstvom za razlučivanje kako je definirano u bilo kojem od zahtjeva 1, 2 ili 3 nakon dodavanja sredstva za razlučivanje u reakcijsku smjesu.
A process according to any one of claims 1 to 8 wherein the reaction mixture under a) is seeded with seeds of the salt of (aS,βR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol and the resolution agent as defined in any one of claims 1, 2 or 3 before and after adding the resolution agent to the reaction mixture. 
Postupak prema bilo kojem od zahtjeva 1 do 8 naznačen time da reakcijska smjesa iz a) je zametnuta sa zametcima soli (aS,βR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola i sa sredstvom za razlučivanje kako je definirano u bilo kojem od zahtjeva 1, 2 ili 3 prije i nakon dodavanja sredstva za razlučivanje u reakcijsku smjesu.
A process according to claim 12 wherein the suitable solvent is an aprotonic polar solvent. 
Postupak prema zahtjevu 12 naznačen time da je pogodno otapalo polarno aprotonsko otapalo.
A process according to any one of claims 1 to 18 wherein the liberation of the base from the salt under d) is performed by reacting the salt in a suitable solvent with a suitable base. 
Postupak prema bilo kojem od zahtjeva 1 do 18 naznačen time da se oslobađanje baze iz soli iz kraka d) je provodi pomoću reakcije soli u pogodnom otapalu sa pogodnom bazom.
A process according to claim 19 wherein the suitable solvent is an organic solvent which is immiscible with water or aqueous salt solutions. 
Postupak prema zahtjevu 19 naznačen time da pogodno otapalo je organsko otapalo koje se ne miješa s vodom ili vodenim otopinama soli.
A process according to any one of claims 1 to 25 wherein the amount of the resolution agent ranges from 0.5 to 1,5 equivalents calculated on the sum of the stereoisomeric forms of 6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol present in the mixture under a). 
Postupak prema bilo kojem od zahtjeva 1 do 25 naznačen time da je količina sredstva za razlučivanje u rasponu od 0.5 do 1,5 ekvivalenata računano na bazi zbroja stereoizomernih oblika 6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola koji se nalazi u smjesi iz koraka a).
A process according to claim 25 wherein the amount of the resolution agent is 1 equivalent calculated on the sum of the stereoisomeric forms of 6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-β-phenyl-3-quinolineethanol present in the mixture under a). 
Postupak prema zahtjevu 25 naznačen time je količina sredstva za razlučivanje je 1 ekvivalent računano na bazi zbroja stereoizomernih oblika 6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-β-fenil-3-kinolinetanola koji se nalazi u smjesi iz koraka a).
reacting 3-benzyl-6-bromo-2-methoxyquinoline with lithium-diisopropylamide and (3-dimethylamino)-1'-propionaphthone in a suitable solvent, followed by adding a suitable acid; 
reakcije 3-benzil-6-bromo-2-metoksikinolina sa litijevim-diizopropilamidom i (3-dimetilamino)-1'-propionaftonom u pogodnom otapalu, nakon čega slijedi dodavanje pogodne kiseline;
A process according to claim 31 wherein the suitable solvent under c) is an alcohol or an ether/alcohol mixture. 
Postupak prema zahtjevu 31 naznačen time da pogodno otapalo pod c) je alkohol ili smjesa eter/alkohol.
A process according to claim 31 wherein the suitable solvent under c) is an alcohol. 
Postupak prema zahtjevu 31 naznačen time da pogodno otapalo pod c) je alkohol.
The compound of claim 1, wherein the PEG has a molecular weight in the range from about 17.5 kDa to about 25 kDa. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što PEG ima molekulsku težinu u rasponu od otprilike 17,5 kDa do otprilike 25 kDa.
The compound of claim 1 or claim 2, wherein the PEG has a molecular weight in the range from about 20 kDa to about 25 kDa. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što PEG ima molekulsku težinu u rasponu od otprilike 20 kDa do otprilike 25 kDa.
The compound of any one of claims 1 to 4, further characterized by being capable of having a peak to trough ratio of less than 2 upon parenterally administering to a patient a therapeutically effective amount of the compound. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što dodatno može imati omjer brijeg/dol manji od 2 prilikom parenteralne primjene na pacijentu terapijski djelotvorne količine spoja.
A pharmaceutical composition comprising a compound of any one of claims 1 to 5 and one or more pharmaceutically acceptable excipients, diluents, or carriers. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5 i jednu ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili podloga.
The pharmaceutical composition of claim 8, further comprising a TRIS buffer at a concentration in the range from about 10 mM to about 25 mM TRIS wherein the pH of said pharmaceutical composition is from about pH 7.0 to about pH 8.0 and at least one isotonicity agent, wherein the composition has an isotonicity between about 270 mOsm and about 330 mOsm. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži TRIS pufer u rasponu koncentracija od otprilike 10 mM do otprilike 25 mM TRIS, gdje je pH navedenog farmaceutskog pripravka od otprilike pH 7,0 do otprilike pH 8,0 i najmanje jedno sredstvo za izotoniziranje, gdje je izotoničnost pripravka između otprilike 270 mOsm i otprilike 330 mOsm.
The pharmaceutical composition of claim 8, further comprising a phosphate buffer at a concentration in the range from about 5 mM to about 10 mM and wherein the pH of said pharmaceutical composition is from about pH 7.0 to about pH 7.5 and at least one isotonicity agent, wherein the composition has an isotonicity between about 270 mOsm and about 330 mOsm. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži fosfatni pufer u rasponu koncentracija od otprilike 5 mM do otprilike 10 mM, gdje je pH navedenog farmaceutskog pripravka od otprilike pH 7,0 do otprilike pH 7,5, i najmanje jedno sredstvo za izotoniziranje, gdje je izotoničnost pripravka između otprilike 270 mOsm i otprilike 330 mOsm.
The pharmaceutical composition of any one of claims 8 to 11, further comprising a therapeutically effective amount of insulin lispro consisting of an A-chain and a B-chain, wherein the A-chain has the amino acid sequence of SEQ ID NO: 1 and the B-chain has the amino acid sequence of SEQ ID NO: 3; and wherein the A-chain and the B-chain are properly cross-linked. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 8 do 11, naznačen time što dodatno sadrži terapijski djelotvornu količinu inzulina lispro koji se sastoji od A-lanca i B-lanca, gdje A-lanac ima aminokiselinski slijed SEQ ID NO: 1, a B-lanac ima aminokiselinski slijed SEQ ID NO: 3; te gdje su A-lanac i B-lanac odgovarajuće umrežen.
B is the B-chain of insulin lispro and has the amino acid sequence of SEQ ID NO: 3; and P is a PEG having a molecular weight in the range from about 20 kDa to about 40 kDa, and wherein A and B are properly cross-linked and P is attached via an urethane covalent bond to the epsilon-amino group of the lysine at position 28 ofB which comprises reacting the epsilon-amino group of the lysine at position 28 ofB with monomethoxypoly(ethylene glycol) p-nitrophenyl carbonate (mPEG-NPC) having a weight average molecular weight of between about 20 kDa and about 40 kDa in an aqueous solvent at a pH between about 8.5 and about 11.5 and at between about 25°C and about 30°C for a period of time between about 3 and about 6 hours. 
B je B-lanac inzulina lispro i ima aminokiselinski slijed SEQ ID NO: 3; i P je PEG čija je molekulska težina u rasponu od otprilike 20 kDa do otprilike 40 kDa, te gdje su A i B odgovarajuće umreženi, a P je vezan preko uretanske kovalentne veze na ε-amino skupinu u lizinu na položaju 28 u B, naznačen time što se sastoji u reakciji ε-amino skupine u lizinu na položaju 28 u B s monometoksipoli(etilen-glikol)p-nitrofenil-karbonatom (mPEG-NPC) s prosječnom molekulskom težinom između otprilike 20 kDa i otprilike 40 kDa, u vodenom otapalu, na pH između otprilike 8,5 i otprilike 11,5 i između otprilike 25 °C i otprilike 30 °C, u trajanju između otprilike 3 i otprilike 6 sata.
HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof, 
inhibitor reduktaze HMG-Co-A ili njegova farmaceutski prihvatljiva sol,
angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 
antagonist receptora angiotenzina II ili njegova farmaceutski prihvatljiva sol,
angiotensin converting enzyme (ACE) Inhibitor or a pharmaceutically acceptable salt thereof, 
inhibitor angiotenzina koji pretvara enzime (ACE) ili njegova farmaceutski prihvatljiva sol,
calcium channel blocker or a pharmaceutically acceptable salt thereof, 
blokator kanala kalcija ili njegova farmaceutski prihvatljiva sol,
aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof, 
inhibitor sinteze aldosterona ili njegova farmaceutski prihvatljiva sol,
aldosterone antagonist or a pharmaceutically acceptable salt thereof, 
antagonist aldosterona ili njegova farmaceutski prihvatljiva sol,
dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof, (viii) endothelin antagonist or a pharmaceutically acceptable salt thereof, 
dvojni inhibitor angiotenzina koji pretvara enzime / neutralne endopeptidaze (ACE/NEP) ili njegova farmaceutski prihvatljiva sol, (viii) antagonist endotelina ili njegova farmaceutski prihvatljiva sol,
providing an arrangement of packages individually wrapped in a filmic polyolefinic material; 
aranžiranju pakiranja pojedinačno umotanih u filmski poliolefinski materijal;
arranging the individually wrapped packages in an ordered configuration in contact with polyolefinic sealing layer A of the naked collation film; and 
slaganju pojedinačno umotanih pakiranja na uređen način u kontaktu s poliolefinskim brtvenim slojem A golog kolacijskog filma;
wrapping the naked collation film around the ordered configuration of individually wrapped packages to form a film tube with overlapping edges. 
omatanju golog kolacijskog filma oko uređene konfiguracije pojedinačno umotanih pakiranja kako bi se načinilo filmsku cijev s preklopljenim rubovima;
The compound for use of claim 4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R7 is methyl; or wherein Rd is -C(O)-(C1-C6)alkyl; or wherein Rd is -C(O)-CH2-O-(C1-C6)alkyl. 
Spoj u skladu s patentnim zahtjevom 4, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time što Rd je -C(O)-(C1-C6)alkil; ili što Rd je -C(O)-CH2-O-(C1-C6)alkil.
submitting a compound of formula (IV) to radical brominaton to form a compound of formula (V); 
podvrgavanje spoja formule (IV) radikalskom bromiranju pri čemu nastaje spoj formule (V);
iii) transforming a compound of formula (V) into the corresponding nitrile derivative of formula (VI); 
pretvorba spoja formule (V) u odgovarajući nitrilni derivat spoja formule (VI), [image]
iv) reacting a compound of formula (VI) with 1,2-dibromoethane to form a compound of formula (VII); and 
reakcija spoja formule (VI) sa 1,2-dibrometanom čime nastaje spoj formule (VII), te [image]
hydrolyzing a compound of formula (VII) to obtain a compound of formula (I). 
hidroliza spoja formule (VII) pri čemu nastaje spoj formule (I).
The process as claimed in claim 1, further comprising the steps of isolating and crystallising the compound of formula (I). 
Postupak kako je prijavljen u patentnom zahtjevu 1, naznačen time da nadalje obuhvaća korake izolacije i kristalizacije spoja formule (I).
The process as claimed in claim 1 or 2 wherein step (i) is carried out in the presence of a palladium catalyst selected from the group consisting of tetrakis(triphenylphosphine)palladium, palladium on activated charcoal, and palladium on alumina. 
Postupak kako je prijavljen u patentnim zahtjevima 1 do 3, naznačen time da se korak (i) provodi u prisutnosti paladija kao katalizatora odabranog od sljedećih: tetrakis(trifenilfosfin)paladj, paladij na aktivnom ugljenu ili paladij na aluminijevom oksidu.
An electrical household appliance as in Claim 3 wherein said cylindrical portion (25) comprises longitudinal grooves (24) on the inner surface of said cylindrical portion (25) for receiving part of said rollers (13). 
Električni kućanski uređaj prema Zahtjevu 3 gdje cilindrični dio (25) obuhvaća longitudinalne utore (24) na unutarnjoj površini cilindričnog dijela (25) za primanje dijelova valjaka (13).
An electrical household appliance as in any previous claims wherein said handle units (11) comprise leveling means (27) which can selectively be fixed on a position adjustment support (28) associated with said second plate. 
Električni kućanski uređaj kao u bilo kojem prethodnom zahtjevu gdje dijelovi (11) ručke obuhvaćaju sredstva za niveliranje (27) koja se selektivno mogu fiksirati na potporu za fiksiranje položaja (28) povezanu s drugom pločom.
An electrical household appliance as in Claim 6 wherein said leveling means (27) has a lower end (28) engageable with a groove (31) associated with the lower plate. 
Električni kućanski uređaj prema Zahtjevu 6 gdje dio za niveliranje (27) ima niži kraj (28) koji se može zahvatiti u utor (31) povezan s donjom pločom.
An electrical household appliance as in Claim 8 wherein said selection pin (29) is positioned on the internal surface of said handle body (18) to be trapped in a respective slot (32) by means of a spring (33). 
Električni kućanski uređaj prema Zahtjevu 8 gdje je selekcijska igla (29) smještena na unutarnjoj površini tijela ručke (18) kako bi bila uhvaćena u odgovarajući otvor (32) putem opruge (33).
A compound that is an indole derivative of formula (I), or a pharmaceutically acceptable salt thereof: wherein X is -SO2- or *-SO2NR3- wherein the bond marked with an asterisk is attached to Ar1; 
Spoj koji je derivat indola formule (I), ili njegova farmaceutski prihvatljiva sol: [image] gdje X je -SO2- ili *-SO2NR3- gdje je veza označena zvjezdicom spojena na Ar1;
A compound as claimed in claim 1 or claim 2 wherein X is *-SO2NR3- wherein the bond marked with an asterisk is attached to Ar1. 
Spoj prema zahtjevu 1 ili zahtjevu 2 gdje X je *-SO2NR3- gdje je veza označena zvjezdicom spojena na Ar1.
A compound as claimed in any of claims 1 to 9 for the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis. 
Spoj prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju astme, kronične opstruktivne plućne bolesti, rinitisa, sindroma alergije dišnih putova ili alergijskog rinobronhitisa.
A pharmaceutical composition that comprises a disaccharide and a compound of general formula (I): wherein R1 is selected from the group consisting of -CH2-N(Ra)2 and - CH2-ORa, where each Ra is independently selected from the group consisting of H, alkyl-CO-, haloalkyl-CO-, cycloalkylalkyl-CO-, haloalkyl-O-CO-, arylalkyl-CO-, arylalkenyl-CO-, heteroaryl-CO-, alkenyl-CO-, alkyl, alkenyl and amino acid acyl, or the two Ra groups together with the N atom of -CH2-N(Re)2 form a heterocyclic group; 
Farmaceutska smjesa koja sadrži disaharid i spoj opće formule (I): [image], naznačena time, što se R1 bira iz grupe koja sadrži -CH2-N(Ra)2 i -CH2-ORa, gdje je svako Ra nezavisno odabrano iz grupe koja sadrži H, alkil-CO-, haloalkil-CO-, cikloalkilalkil-CO-, haloalkil-O-CO-, arilalkil-CO-, arilalkenil-CO-, heteroaril-CO-, alkenil-CO-, alkil, alkenil i aminokiselinski acil ili dvije Ra grupe zajedno sa N atomom iz -CH2-N(Ra)2 formiraju heterocikličnu grupu;
A composition according to claim 5, wherein the ratio (w/w) of compound to disaccharide is from 1:100 to 1:400. 
Smjesa prema zahtjevu 5, naznačena time, što odnos (tež,/tež.) spoja prema disaharidu iznosi od 1:100 do 1:400.
A composition according to claim 6, wherein the ratio (w/w) of compound to disaccharide is about 1:200. 
Smjesa prema zahtjevu 6, naznačena time, što odnos (tež,/tež.) spoja prema disaharidu iznosi oko 1:200.
A composition comprising 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, a crystallization inhibitor selected from the group consisting of hydroxypropylmethylcellulose, polyvinylpyrrolidone, and hydroxypropylcellulose, and a pH modifier, said composition providing a measurable improvement in dissolution rate of the 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof 
Smjesa koja sadrži 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1- il)-4-okso-1,4-dihidrokinolin-3-karboksilnu kiselinu ili njezinu sol, inhibitor kristalizacije izabran iz skupine koja obuhvaća hidroksipropilmetilcelulozu, polivinilpirolidon i hidroksipropilcelulozu te modifikator pH, naznačena time, da smjesa ima mjerljivo poboljšan stupanj otapanja 1-(6- amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-il)-4-okso-1,4- dihidrokinolin-3-karboksilne kiseline ili njezine soli.
Use of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, a crystallization inhibitor selected from the group consisting of hydroxypropylmethylcellulose, polyvinylpyrrolidone, and hydroxypropylcellulose, and a pH modifier for the manufacture of a composition providing a measurable improvement in dissolution rate of the 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydxoquinoline-3-carboxylic acid or a salt thereof for treating disease in a patient by administering thereto said composition. 
Uporaba 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-il)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli, inhibitora kristalizacije izabranog iz skupine koja obuhvaća hidroksipropilmetilcelulozu, polivinilpirolidon i hidroksipropilcelulozu te modifikatora pH za proizvodnju smjese, naznačena time, da ima mjerljivo poboljšan stupanj otapanja 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-il)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli za liječenje bolesti kod bolesnika kojemu će se dati ta smjesa.
Method for partial discharge testing of an insulation component (2), comprising the following steps: 
Metoda za ispitivanje djelomičnog izboja izolacijske komponente (2), koja se sastoji od sljedećih koraka:
applying an AC voltage (12) to the insulation component (2), 
primjene izmjeničnog napona (12) na izolacijsku komponentu (2),
measuring the partial discharge induced by the at least one X-ray pulse (7; 13; 14), characterized in that the dose rate of the at least one X-ray pulse (7; 13; 14) inside the insulation component (2)is at least 10-2 Gray/s, wherein the duration of the at least one X-ray pulse corresponds to the recombination time of free electrons and ions inside a void filled with one or more gases. 
mjerenja djelomičnog izboja induciranog najmanje jednim rendgenskim impulsom (7; 13; 14), karakterizirana time što stopa doziranja najmanje jednog rendgenskog impulsa (7; 13; 14) u izolacijskoj komponenti (2) iznosi najmanje 10-2 Gray/s, pri čemu trajanje najmanje jednog rendgenskog impulsa odgovara vremenu rekombinacije slobodnih elektrona i iona u šupljini ispunjenoj najmanje jednim plinom.